Apollon Wealth Management LLC Boosts Stake in Gilead Sciences, Inc. $GILD

Apollon Wealth Management LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,780 shares of the biopharmaceutical company’s stock after purchasing an additional 871 shares during the quarter. Apollon Wealth Management LLC’s holdings in Gilead Sciences were worth $3,967,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Southland Equity Partners LLC raised its position in Gilead Sciences by 2.9% in the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after purchasing an additional 92 shares during the period. Twelve Points Wealth Management LLC raised its position in Gilead Sciences by 1.5% in the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 98 shares during the period. Argentarii LLC raised its position in Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after purchasing an additional 99 shares during the period. Investment Research & Advisory Group Inc. raised its position in Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 100 shares during the period. Finally, Lodestar Private Asset Management LLC raised its position in Gilead Sciences by 3.6% in the first quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 100 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.4%

Gilead Sciences stock opened at $117.18 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $84.17 and a fifty-two week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a market capitalization of $145.40 billion, a P/E ratio of 23.34, a PEG ratio of 0.80 and a beta of 0.34. The stock has a 50-day simple moving average of $114.65 and a 200-day simple moving average of $110.26.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the previous year, the business earned $2.01 EPS. The business’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the sale, the chief financial officer directly owned 159,555 shares of the company’s stock, valued at $18,120,661.35. This represents a 1.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider directly owned 113,193 shares of the company’s stock, valued at approximately $12,855,329.01. This represents a 2.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,402,130 in the last ninety days. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on GILD shares. Rothschild & Co Redburn lifted their price objective on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Finally, Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research note on Friday, July 25th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $118.08.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.